Abecma denied as not medically necessary by Humana?

Humana's specific coverage criteria for abecma are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Abecma on Medical-Necessity Grounds

Abecma (idecabtagene vicleucel) is a CAR-T cell therapy approved for relapsed or refractory multiple myeloma. Humana's medical-necessity review applies criteria drawn from its published coverage policy and from guidelines issued by the National Comprehensive Cancer Network (NCCN). Denials on this basis typically mean the reviewer concluded the clinical record did not clearly document that the patient meets each criterion the policy requires — such as the number and type of prior therapy lines, refractory status, performance status, or organ-function standards. Because the criteria are detailed and the documentation review is often conducted by a non-specialist, gaps in records rather than genuine clinical ineligibility are a common driver.

## Your Right to Appeal

Federal law gives you meaningful appeal rights. If your coverage is through an employer-sponsored plan governed by ERISA, the plan must provide a full-and-fair review under ERISA §503, including access to the information used to make the decision. Under ACA §2719, most plans must also offer an external review by an independent organization. You generally have approximately 180 days from denial to request internal appeal, and external review must typically be requested within four months after exhausting internal appeals — check your denial letter for the exact deadlines. An expedited appeal (decision within 72 hours) is available when the standard timeline would seriously jeopardize your health.

## Building Your Appeal

A strong Abecma medical-necessity appeal rests on four documentation categories:

1. Diagnosis confirmation — pathology reports, bone marrow biopsy results, and imaging confirming relapsed or refractory multiple myeloma. 2. Prior therapy history — a chronological list of every prior regimen with start and end dates, best response achieved, and documented reason for discontinuation (progression, toxicity, or lack of response). Cross-reference this directly against the eligibility language in both the FDA-approved prescribing information and Humana's published coverage policy. 3. Clinical severity and performance status — chart documentation of current disease burden, functional status assessments, and treating-physician narrative of why standard alternatives are no longer appropriate. 4. Prescriber medical-necessity letter — a letter from the treating hematologist or oncologist that maps every policy criterion explicitly to a documented chart fact, cites the applicable NCCN guideline, and explains why Abecma is the appropriate next treatment.

## Criteria-Mapping Structure

Create a two-column table. In the left column, paste each eligibility requirement verbatim from (a) the FDA-approved Abecma prescribing label and (b) Humana's published medical policy for this therapy. In the right column, cite the specific chart record — date, document name, and finding — that satisfies each requirement. Submit this table with your appeal letter so the reviewer cannot miss the correspondence. If any criterion is genuinely met but not yet documented, ask the treating physician to add a progress note before filing.